Upper <scp>GI</scp> biopsies for adenocarcinoma – how many biopsies should endoscopists take?

Philip Kaye(Nottingham University Hospitals NHS Trust), Krish Ragunath(Nottingham University Hospitals NHS Trust), Daniel Lindsay(Royal Hospital Chelsea), Craig Platt(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), James Catton(Nottingham University Hospitals NHS Trust), Ravinder Vohra(Nottingham University Hospitals NHS Trust)
Histopathology
December 28, 2018
10.1111/his.13816
Cited by 8

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process
|Gastroenterology|2012|378
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374